Cantuzumab ravtansine
Cantuzumab ravtansine (pronunciation: can-tu-zu-mab rav-tan-sine) is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Immunogen Inc., a biotechnology company that specializes in antibody-drug conjugates.
Etymology
The name "Cantuzumab ravtansine" is derived from the components of the drug. "Cantu-" refers to the target of the antibody, the Cantu syndrome associated protein. "-zumab" is a suffix used in the names of humanized monoclonal antibodies. "Ravtansine" refers to the maytansinoid used as the cytotoxic agent in this antibody-drug conjugate.
Mechanism of Action
Cantuzumab ravtansine works by binding to the Cantu syndrome associated protein on the surface of cancer cells. Once bound, the drug is internalized by the cell where the cytotoxic agent, ravtansine, is released. This agent inhibits the growth of the cancer cell by disrupting the process of cell division.
Related Terms
External links
- Medical encyclopedia article on Cantuzumab ravtansine
- Wikipedia's article - Cantuzumab ravtansine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski